Agios Pharmaceuticals, Inc. (AGIO)
AGIO Price and Sentiment
AGIO Latest news
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript2021-11-03 12:45
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for2021-10-27 16:11
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.
Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their own capital, put at risk in order to fill multi-million-$ trade orders placed by institutions managing multi-Billion-$ portfolios.
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:
Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.